Fondaparinux Sodium

Names

[ Name ]:
Fondaparinux Sodium

[Synonym ]:
α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium salt
Decasodium methyl 2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-2- O-sulfonato-α-L-idopyranuronosyl-(1->;4)-2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranoside
α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10)
Fondaparin sodium
Arixtra
Fondaparinux sodium
α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4 )-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10)
Fondaparinux (sodium)

Biological Activity

[Description]:

Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> Factor Xa

Research Areas >> Cardiovascular Disease

[Target]

Factor Xa[1]

[In Vitro]

Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs)[2].

[In Vivo]

Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation[1].

[References]

[1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.

[2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

[Related Small Molecules]

Chemical & Physical Properties

[ Molecular Formula ]:
C₃₁H₅₃N₃Na₁₀O₄₉S₈

[ Molecular Weight ]:
1738.16

[ PSA ]:
900.82000

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Articles

Structural Evidence for the Tetrameric Assembly of Chemokine CCL11 and the Glycosaminoglycan Arixtra™.

Biomolecules 3 , 905-22, (2014)

Understanding chemokine interactions with glycosaminoglycans (GAG) is critical as these interactions have been linked to a number of inflammatory medical conditions, such as arthritis and asthma. To b...

Bioengineered heparins and heparan sulfates.

Adv. Drug Deliv. Rev. 97 , 237-49, (2016)

Heparin and heparan sulfates are closely related linear anionic polysaccharides, called glycosaminoglycans, which exhibit a number of important biological and pharmacological activities. These polysac...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.